Unpublished studies on antimalarial drug efficacy have found low levels of chloroquine resis--tance in Yemen. This study was carried out to determine the current prevalence of drug resistance in Plasmodium falciparum in Yemen to the main anti-malarial drugs and to determine the effective concentration (EC) values.
M alaria is the most important parasitic disease of man. The human disease is a protozoan infection of red blood cells transmitted by the bite of the blood-feeding female anopheline mos--quito. Approximately 270 million people suffer from malaria, and there are between one and 2.5 million deaths each year, mostly among African children. 1 Antimalarial drugs fall into three broad groups: the quinoline-related compounds (quinine, quinidine, chloroquine, amodiaquine, halofantrine, primaquine), the antifols (pyrimethamine, proguanil, chlorproguanil, trimethoprim), and artemisinin compounds (artemis--inin, artemether, artesunate). Of these, the artemisinin drugs have the broadest time window of action on the asexual malaria parasites, from the medium-sized rings to early schizonts, and produce the most rapid thera--peutic responses. 2, 3 The problem of drug resistance is most important
The prevalence and degree of resistance of Plasmodium falciparum to first-line antimalarial drugs: an in vitro study from a malaria endemic region in Yemen with Plasmodium falciparum. There is widespread but patchy resistance to proguanil and pyrimethamine wherever Plasmodium falciparum occurs. Chloroquine resistance has been known for years in parts of Southeast Asia, South America and Oceania. In the past decade, the prevalence and degree of chloroquine resistance have increased greatly in sub-Saharan Africa, at first in the east and later in the west of the conti--nent. 4, 5 In Yemen, several unpublished studies on anti--malarial drug efficacy were carried out in the past two decades in the southern parts of the country by WHO consultants for malaria control. Their results showed a low level of chloroquine resistance, and although it ap--pears to be not totally resistant, chloroquine remains a useful first-line therapy in Yemen. 6, 7 The main purpose of this study was to describe the state of drug-resistant malaria and to outline current thinking regarding strategies to limit the advent, spread and intensification of drug-resistant malaria in Yemen. No selectivity parameters were taken except those required for the Mark III in vitro test technique. 8 Informed consent was obtained from patients or their parents. Fever was defined as a body temperature of 37.5°C or above. Patients were asked for any history of diarrhea and vomiting.
SUBJECTS AND METHODS

This
Any history of antimalarial drug ingestion within the past 2-4 weeks was an exclusion criteria. Only pa--tients with negative urine tests to four aminoquinolines and sulphonamides were enrolled. Patients with com--plicated disease such as cerebral malaria, anemia, jaun--dice and bronchopneumonia were excluded. Enrolled patients were registered and given special codes. The diagnosis for all the patients was confirmed by the pres--ence of asexual forms (trophozoite) of P. falciparum in the peripheral blood smear (thick film) and by the im--munochromatography (HRP2) method as confirma--tion. Patients with mixed infections (P. falciparum, P. malariae or P. ovale) were excluded from the study.
Patients whose parasite count was not less than 1 000 and not more than 80 000 asexual parasites per mm 3 of blood were selected. The WHO in vitro anti--malarial drugs susceptibility test (Mark III) technique 8 was used to determine the antimalarial drugs suscepti--bility of the P. falciparum isolates. The first choice drugs for malaria, which include chloroquine, quinine and ar--temisinin, were tested.
Data analysis was carried out using test-record sheets and the porbit analyzing program (WHO ana--lyzing program) for interpretation of results.
RESULTS
During the 12 months of the study period, 219 Plasmodium falciparum malaria patients met our study criteria for parasite density in their blood. They com--prised 156 males and 63 females; 183 passed the urine test for antimalarial drug absence (Table 1) . For the 602 tests, the rate of successful schizont growth for the four drugs was 42% ( Table 2 ). The frequency and percent--age of P. falciparum schizont maturation for the differ--ent concentrations of the antimalarial drugs is shown in Table 3 . The level of chloroquine resistance (cut-off indicating resistance) was calculated to be 8 pmol/well. At this cut-off, 47% of isolates showed resistance to chloroquine. The chloroquine values show the growth of five different schizonts at five different concentra--tions of chloroquine, which suggests the occurrence of five different strains of P. falciparum among our study patients. The cut-off for mefloquine was calculated to be 32 pmol/well with 5.2% of tested schizonts showing resistance to mefloquine. No resistance against quinine or artemisinin occurred in our study as indicated by no growth at the cut-off level (Table 3) . Table 4 shows the schizont maturation rate for all drugs. Effective concen--trations (EC) in blood for sensitive and resistant isolates are shown in Table 5 . The EC50 and EC95 values for mefloquine that inhibited schizont maturation in resis--tant isolates were higher than the normal therapeutic level for mefloquine.
DISCUSSION
In our study, the first reason for selecting in vitro testing was that the alternative in vivo test used for the same purpose by WHO may be influenced by host factors such as malabsorption, immunity and other unpredict--able factors, whereas our tool is not affected. In addi--tion, the interpretations of the WHO in vivo test may be complicated in the case of resistance type I by re-in--fection during the 28-day follow-up period. The second reason is that in vitro testing can be done to test several types of drugs and drug combinations with different concentrations, while in vivo tests cannot. The third reason is that in vivo testing may lead to severe progres--sion in a patient if the P. falciparum resists the tested drug, which may lead to complication and life-threat--ening infection, while with in vitro testing the patient can be treated with suitable drugs after collection of the specimen, and the failure of inhibition of P. falciparum in the well would not effect the patient' s situation. In vitro testing was performed 183 times for chloroquine, 165 times for mefloquine, 138 times for quinine and 116 times for artemisinin. In total, 42.5% of in vitro testing of schizont maturation was successfully recorded, while 57.5% were affected by bacterial contamination or fail--ure of schizont growth. Bacterial contamination occurs easily in field studies where the tests are carried out in remote areas without enough facilities to make the place of work sterile enough to prevent contamination of the culture wells. Cross-contamination during plate disposing and/or during harvesting procedures also can be a factor. In addition, the original contamination of the plates during preparation by the producer could not be excluded. Similar problems of high contamination have faced other researchers in malaria foci in Africa and Southeast Asia. 9 The second problem was the failure of growing schizonts when there was no bacterial contamination. This might be due to the presence of antimalarial drugs in patient plasma in spite of negative results for the presence of antimalarial drugs in urine. Several recent reports confirm this suggestion and refer these phe--nomena to the long half-life of antimalarial drugs in plasma despite disappearance from urine. In addition, this failure may be related to technical errors (which are also quite common) such as pH change of the medium, 
Chloroquine
In Yemen, the occurrence of chloroquine-resistant P. falciparum strains were noticed in the early 1990s. In the last year, WHO and the National Malaria Control Program conducted an in vivo study to estimate chloro--quine resistance in Tihamah, and their results showed that in more than 40% of the sample there was treat--ment failure in either early or late stages. 6, 7 The WHO and our study confirmed the occurrence of chloroquineresistant P. falciparum and indicated that the rate was rising slowly, but eventually was expected to increase and spread over all the foci of malaria in Yemen due to several reasons, the main reason being that chloroquine is one of the most widely consumed drugs in Yemen. 6, 7 Others reasons are the high frequency of self-medica--tion, inadequate dosing, and sub-therapeutic levels in the blood. These factors are believed to be predominant factors that contribute to chloroquine resistance in P. falciparum, not only in Yemen but also in most third world countries. 11, 12 One of the main aims of our study was to determi--nate the EC95. This result was needed to estimate the effective therapeutic drug level in the human body. Our results showed the EC95 for chloroquine was 12.26 µmol/L of blood. This result indicates a high resistance of P. falciparum for chloroquine among the study cases, and this is confirmed by the EC95 which was equal to the 1.5 times (8 µmol/L blood) the therapeutic level re--quired for treating cases of P. falciparum worldwide by chloroquine. 2, 11, 13 Mefloquine Mefloquine is a quinoline methanol compound available only for oral administration. It has a terminal elimina--tion half-life of 2 to 3 weeks in patients with malaria. 14, 15 P. falciparum mefloquine resistance has been reported from Southeast Asia and Africa. 16, 17 In Yemen, no re--search has been done to study mefloquine resistance, so our study is the first in vitro test of mefloquine and the first to report the presence of mefloquine-resistant P. falciparum in Yemen. The resistance rate in our study was 5.6%. Our prevalence rate was lower than those re--ported from Africa (range from 20% to 65%) and from Southeast Asia (range, 30 to 80%). 18, 19 Of the 11 isolates of mefloquine-resistant strains, 8 exhibited successful growth in 16 pmol/well (equivalent to 3.2×10 -6 mol/ L blood), which is the therapeutic level, and three iso--lates show a high degree of resistance growing in the 32 pmol/well (equivalent to 6.4×10 -6 mol/L blood), which demonstrates that the mefloquine-resistant strains can adapt up to double the therapeutic level. In addition, the EC50 (1.4971 µmol/L blood) and EC95 (4.4971 µmol/L blood) confirmed resistance since these values are higher than the normal therapeutic level for meflo--quine.
20
Quinine Reports of quinine resistance are still rare in Middle East countries, but a high rate of true resistance has been reported from Thailand (50%) and clinical failure of the quinine test has been reported from Africa. 21, 22 In our study, no quinine resistance occurred and isolates of P. falciparum are still sensitive to quinine even at low concentrations of the drug, since the data show that the (SMI) schizont maturation index percentage of 97.6 occurred at 0.64 µmol/L blood. The high efficiency of quinine in Yemen is different from that reported in East Africa and other Middle East countries where there is a steady increase in the time parasites take to disappear from the blood after treatment with quinine.
21,22
Artemisinin
The most important development in recent years has been the discovery and development of drugs related to artemisinin in China. 23 This drug is the best drug avail--able for treatment of severe malaria in malaria drugresistant P. falciparum areas. No resistance occurred in our study to artemisinin and the tested isolates were still very sensitive to low doses of the drug. Our result is similar to results reported from malaria foci worldwide where no artemisinin primary resistance was reported for the SMI (96%) of the isolates at 5.0 pmol/well and the EC95 was 1.64 pmol/well. Our study confirmed both the occurrence of chloro--quine-resistant P. falciparum and a slow increase in the rate of this resistance. It is likely that resistance will in--crease further and spread over all the foci of malaria in Yemen. It is recommended that the policy of treatment of malaria infection in the foci of chloroquine resistance be modified. The use of the combination of pyrimeth--amine/sulfadoxine as the first choice of treatment is recommended to avoid the spread of chloroquine-resis--tant P. falciparum. Investigation of the prevalence and degree of resistance of P. falciparum in malaria endemic foci in Yemen, and continual monitoring of the increas--ing resistance rate, is recommended as well. A molecular study to find out the drug-resistant P. falciparum strains in Yemen, which this study suggests to be five in number, is also needed. A low rate of mefloquine resistance in P. falciparum is present in Yemen, and it is lower than rates reported from Africa and Southeast Asia. To prevent the further development of mefloquine-resistance in Yemen, the drug should never be used in isolation and a combi--nation with sulfadoxine and pyrimethamine should be used. Finally, no quinine or artemisinin resistance oc--curred and isolates of P. falciparum are still sensitive to quinine and artemisinin even at low concentrations of both drugs. The SMI percentage, EC90, and EC95 of both drugs should be evaluated from time to time and correlated with previous results. This will provide good information about the situation of these drugs in Yemen as well as for other drugs and combinations.
